SakulaA.A history of asthma: the FitzPatrick Lecture 1987. JR Coll Physicians Lond1988;22(1):36–44.
2.
WebbJ., ReesJ., ClarkTJ.A comparison of the effects of different methods of administration of beta-2 sympathomimetics in patients with asthma. Br J Dis Chest1982;76(4):351–357.
3.
ReddelH., WareS., MarksG., SalomeC., JenkinsC., WoolcockA.Differences between asthma exacerbations and poor control. Lancet1999;353(9150):364–369.
4.
SpeizerFE., DollR., HeafP.Observations on recent increase in mortality from asthma. Br Med J1968;1(5588):335–339.
5.
BlauwGJ., WestendorpRGJ.Asthma deaths in New Zealand: whodunnit? (editorial)Lancet1995;345(8941):2–3.
6.
CampbellMJ., CogmanGR., HolgateST., JohnstonSL.Age specific trends in asthma mortality in England and Wales, 1983-95: results of an observational study. BMJ1997;314(7092):1439–1441.
7.
van Essen-ZandvlietEE., HughesMD., WaalkensHJ., DuivermanEJ., PocockSJ., KerrebijnKF.Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-Specific Lung Disease Study Group. Am Rev Respir Dis1992;146(3):547–554.
8.
BisgaardH., MollerH.Changes in risk of hospital readmission among asthmatic children in Denmark, 1978-1993. BMJ1999;319(7204):229–230.
9.
LaitinenLA., LaitinenA.Mucosal inflammation and bronchial hyperreactivity (review). Eur Respir J1988;1(5):488–489.
10.
United States Food and Drug Administration. Division of Pulmonary Drug Products. Class labeling for intranasal and orally inhaled corticosteroid containing drug products regarding the potential for growth suppression in children. November 9, 1998. http://www.fda.gov/eder/news/cs-label.htm. Accessed May 15. 2000.
11.
LipworthBJ.New perspective on inhaled drug delivery and systemic bioactivity (review). Thorax1995;50(2):105–110.
12.
PedesenS.Inhalers and nebulizers: which to choose and why (review). Respir Med1996;90(2):69–77.
13.
AgertoftL., PedersonS.Final height of asthmatic children treated for 7-11 years with inhaled budesonide (abstract). Am J Respir Crit Care Med1998;157(4 Pt 2):A711.
14.
PatersonIC., CromptonGK.Use of pressurised aerosols by asthmatic patients. Br Med J1976;1(6001):76–77.
15.
ThorssonL., EdsbackerS.Lung deposition of budesonide from a pressurised metered-dose inhaler attached to a spacer. Eur Respir J1998;12(6):1340–1345.
16.
FriegangB.New method of beclomethasone aerosol administration to children under 4 years of age. Can Med Assoc J1977;117(11):1308–1309.
17.
NewmanSP., MillarAB., Lennard-JonesTR., MorenF., ClarkeSW.Improvement of pressurised aerosol deposition with Nebuhaler spacer device. Thorax1984;39(12):935–941.
18.
JanssensHM., DevadasonSG., HopWCJ., Le SouefPN., De JongsteJC., TiddensHA.Variability of aerosol delivery via spacer devices in young asthmatic children in daily life. Eur Respir J1999;13(4):787–791.
19.
DaviesHA., LennardL., LilleymanJS.Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance?BMJ1993;306(6887):1239–1240.
20.
GibsonNA., FergusonAE., AitchisonTC., PatonJY.Compliance with inhaled medication in preschool children. Thorax1995;50(12):1274–1279.
21.
BraunsteinGL., TrinquetG., HarperAE., Compliance Working Group. Compliance with nedocromil sodium and a nedocromil sodium/salbutamol combination. Eur Respir J1996;9(5):893–898.
22.
MilgromH., BenderB., AckersonL., BowryP., SmithB., RandC.Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol1996;98(6 Pt 1):1051–1057.
23.
ArmitageJM., WilliamsSJ.Inhaler technique in the elderly. Age Ageing1988;17(4):275–278.
24.
EverardML.Delivering aerosolised drugs to distressed children is a thankless task. Arch Dis Child2000;82:428.
25.
KellowayJS., WyattRA., AdlisSA.Comparison of patients compliance with prescribed oral and inhaled asthma medications. Arch Int Med1994;154:349–351.
26.
Health literacy: report of the Council of Scientific Affairs. Ad Hoc Committee on Health Literacy for the Council of Scientific Affairs, American Medical Association. JAMA1999;281(6):552–557.
27.
HananiaNA., WittmanR., KestenS., ChapmanKR.Medical personnel's knowledge of and ability to use inhaling devices: metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest1994;105(1):111–116.
28.
EverardML., DolovichM.In vivo measurements of lung dose. In: Drug delivery to the lung: clinical aspects. BisgaardH., O'CallaghanC., SmaldoneG., editors. (In series 'Lung biology in health and disease'). In press.
29.
GoldmanJM., BaystonSM., O'ConnorS., MeighRE.Inhaled micronised gentamicin powder: a new delivery system. Thorax1990;45(12):939–940.
30.
SmithG.A patient's view of cystic fibrosis. J Adolesc Health Care1986;7(2):134–138.